Ive been thinking about this quite a bit, and Im a
Post# of 151671

The issue is the unknowns.
Hows are Nash data?
Can we file the BLA?
Hows the cancer trial going?
If any of these sre stellar it raises the price at which Id vote for a buyout. But if they arent, the price gets uncomfortable IMO

